306 related articles for article (PubMed ID: 18716045)
1. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
3. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
4. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
5. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
7. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
[TBL] [Abstract][Full Text] [Related]
8. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
9. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
[TBL] [Abstract][Full Text] [Related]
11. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L
Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964
[TBL] [Abstract][Full Text] [Related]
13. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
15. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
16. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
Crespillo A; Suárez J; Bermúdez-Silva FJ; Rivera P; Vida M; Alonso M; Palomino A; Lucena MA; Serrano A; Pérez-Martín M; Macias M; Fernández-Llébrez P; Rodríguez de Fonseca F
Biochem J; 2011 Jan; 433(1):175-85. PubMed ID: 20955176
[TBL] [Abstract][Full Text] [Related]
18. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
[TBL] [Abstract][Full Text] [Related]
19. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
